STAMFORD, Conn., June 24, 2026
Knoa Pharma LLC and the Global Coalition for Adaptive Research (GCAR) announced a significant milestone in the development of tinostamustine, an investigational therapy for glioblastoma (GBM), with the first patient randomized to the tinostamustine treatment arm of the GBM AGILE trial and the first recurrent disease patient receiving the therapy. Glioblastoma is the most aggressive and deadly form of primary brain cancer, with limited treatment options and no known cure. The advancement of tinostamustine into the adaptive Phase 2/3 platform trial represents an important step toward evaluating a potential new treatment option for patients facing poor outcomes despite current standards of care. The milestone highlights growing efforts to accelerate innovation in neuro-oncology through more efficient clinical trial designs and collaborative research models.
Novel Dual-Action Therapy Targets Aggressive Brain Tumors
Tinostamustine is a first-in-class investigational therapy that combines two potentially complementary mechanisms of action within a single molecule. The drug integrates bifunctional alkylating activity with pan histone deacetylase (HDAC) inhibition, a strategy designed to enhance anti-tumor effects against difficult-to-treat cancers. The therapy is being investigated as an adjuvant treatment for patients with newly diagnosed glioblastoma following surgery, radiation therapy, and chemotherapy. Additionally, a separate cohort is evaluating its use in patients whose disease has returned after initial treatment. Particular attention is being given to patients with MGMT promoter-unmethylated glioblastoma (uMGMT GBM), a subgroup associated with poorer prognosis and reduced responsiveness to existing therapies. Approximately 60% of newly diagnosed glioblastoma patients fall into this category, creating a substantial unmet medical need for more effective treatment options.
GBM AGILE Platform Designed to Accelerate Drug Development
The GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) study is a groundbreaking adaptive platform trial that allows multiple experimental therapies from different sponsors to be evaluated simultaneously under a single master protocol. Unlike traditional clinical trials, GBM AGILE utilizes a shared control arm and adaptive statistical methodologies to identify promising therapies more efficiently and accelerate decision-making. Data generated through the study may support future New Drug Applications (NDAs) and regulatory submissions to the U.S. Food and Drug Administration (FDA) and other health authorities. By enrolling both newly diagnosed and recurrent glioblastoma patients, the platform provides researchers with opportunities to assess treatment effectiveness across multiple disease settings while reducing development timelines and improving trial efficiency.
Advertisement
Earlier Research Supports Continued Clinical Evaluation
The current investigation builds upon findings from a previous Phase 1 clinical trial involving patients with uMGMT glioblastoma, where tinostamustine demonstrated a favorable tolerability profile at doses ranging from 80 to 100 mg/m². Although the early-stage study was not designed to establish efficacy, exploratory analyses revealed encouraging signals in both progression-free survival and overall survival outcomes. These observations supported the decision to advance the therapy into the GBM AGILE platform for further evaluation. According to company leadership and GCAR investigators, the initiation of patient dosing marks an important milestone in the search for innovative treatments capable of improving outcomes in glioblastoma, a disease that has seen only limited therapeutic progress over the past several decades. As enrollment and evaluation continue, researchers hope the study will provide valuable insights into the potential role of tinostamustine in addressing one of oncology’s most challenging cancers.
Source: Knoa Pharma press release
